- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02383823
Postprandial Lipidemia After a Meal With Different Types of Fat, Estrogen Treatment, Age and Gender in Healthy Subjects
Postprandial Lipidemia and Glucose Metabolism After a Meal With Different Types of Fat, Estrogen Treatment, Age and Gender in Healthy Subjects
The study examines the effect of hormone replacement in postmenopausal women compared to men, 55 years of age, and in the elderly without hormone replacement of both sexes. The lipid and glucose metabolism is evaluated during treatment and placebo with a meal with mashed potatoes and different types of fat. Glucose, insulin, triglyceride, total cholesterol, LDL and HDL cholesterol, free fatty acids and coagulation parameters are measured.
During menopause the women reduce their levels of estrogen and their risk of cardiovascular disease rises to the men's level. This effect on mortality and morbidity can probably be reduced by hormone therapy.
Study Overview
Detailed Description
The experiment illustrates the gender, age and estrogen influence the acute metabolic responses after meal consisting of mashed potatoes added different types of fat. The reason is that the distribution of macronutrients are often not equal to the ideal and fat intake in Western countries is well above the recommended maximum of 30%. A high fat intake -especially saturated fat -increases the risk of ischemic heart disease significantly and HDL cholesterol levels are determined by the postprandial lipid response. The negative correlation between HDL cholesterol and ischemic heart disease can apparently be attributed to a strong positive correlation between postprandial lipidemia and ischemic heart disease.
Diet has an important role in both the development and treatment of diseases such as type 2 diabetes, elevated blood cholesterol, and obesity. It is recommended today to eat a high-carbohydrate and low-fat diet with reduced energy in these patients. Postprandial lipid in the blood after fat meals expected to be gender-specific, since men's total and LDL-cholesterol and triglycerides are higher than in women of childbearing age. Menopause reduces women's estrogen levels and increase their risk of cardiovascular disease to men's level. This effect on morbidity and mortality is influenced probably by hormone replacement. What influence it has on the postprandial responses is uncertain. The haemostatic system plays an important role in the development of ischemic heart disease and in acute conditions such as acute myocardial infarction, unstable angina, and sudden cardiac death. Fat-rich meals induces an acute activation of coagulation factors and postprandial lipid levels in the blood are essential to the development of atherosclerosis and coagulation activation 4 to 8 hours after a meal. The influence of gender, age, estrogen and different fat types of these conditions are not yet fully elucidated. The investigators believe it is important to investigate the effect of addition of different types of fat to a starchy meal on blood glucose, insulin and lipid levels in healthy subjects, since the metabolic responses today considered closely associated to the development of atherosclerosis and type 2 diabetes.
The investigators therefore wish to investigate the effect of hormones in postmenopausal women compared to men and to assess the effect of age in both sexes of acute metabolic responses by examining the age groups 45-55 (40 women in total in 5 different hormone treatments and 8 men) and 65-80 years (16 in total, 8 of each gender).
The effect is assessed on glycemic response, insulin, triglyceride, total cholesterol, LDL and HDL cholesterol, apo-lipoprotein, free fatty acids and coagulation parameters (von Willebrand factor, Factor VII, Factor VIIa, Plasminogen activator inhibitor-1, fibrinogen, tissue thromboplastin, fibrin).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Finn F Lauszus, MD, PhD
- Phone Number: +4578434614
- Email: finlau@rm.dk
Study Contact Backup
- Name: Ole W Rasmussen, MD,DrMedScie
- Phone Number: +4586523654
- Email: olew.rasmussen@dadlnet.dk
Study Locations
-
-
-
Herning, Denmark, 7400
- Gynecology Dept. Herning Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men, age 45-55
- Men age 65-80
- Women age 45-55: The menopausal women's follicle stimulating hormone and luteinizing hormone levels should be above 40 nmol/l
- Women age 65-80
Exclusion Criteria:
- hypercholesterolemia,
- hypertension,
- substance abuse or alcohol abuse
- recognized renal, hepatic, cardiac and metabolic disorders,
- thromboembolic diseases,
- active cancer of the uterus or breast or
- other hormone replacement therapy.
- If pronounced side effects of hormone treatment, the subject is omitted from the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Estrogens in menopausal women
Crossover of estrogens or placebo in random order, either 2 mg estradiol or placebo in three months in random sequence, age span 45-55
|
Crossover study of estrogen or placebo in random order in menopausal women
Other Names:
|
No Intervention: Menopausal men
comparative to menopausal women, age span 45-55
|
|
No Intervention: Elderly women
comparative to menopausal women, age span 65-80
|
|
No Intervention: Elderly men
comparative to menopausal women, age span 65-80
|
|
Placebo Comparator: Placebo in menopausal women
Crossover of estrogen or placebo in random order, either 2 mg estrogen or placebo in three months in random sequence, age span 45-55
|
Crossover study of placebo or estrogen in random order in menopausal women
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postprandial lipidemia
Time Frame: Three months of estrogen treatment
|
Comparison of area under curve of lipids after estrogen treatment with no treatment, gender, and age: Cholesterol, LDL; HDL, TG; FFA: Unit: mmol/L*480 min
|
Three months of estrogen treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postprandial glucose and insulin
Time Frame: Three months of estrogen treatment
|
Comparison of area under curve of glucose (mmol/L * 480 min) and insulin (micro-equivalents/L* 480 min) after estrogen treatment with no treatment, gender, and age
|
Three months of estrogen treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Finn F Lauszus, MD,PhD, Herning Hospital, Denmark
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M-2104-99
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menopause
-
Riphah International UniversityCompleted
-
Englewood Hospital and Medical CenterNanohealth, Inc.WithdrawnMenopause SymptomsUnited States
-
Englewood Hospital and Medical CenterNanohealth, Inc.CompletedMenopause SymptomsUnited States
-
University of Colorado, DenverCompletedMenopause | Pre-menopauseUnited States
-
S.LAB (SOLOWAYS)Center of New Medical TechnologiesCompletedMenopause SymptomsRussian Federation
-
BHR Pharma, LLCTerminatedMenopause Related ConditionsGermany
-
Singapore General HospitalRecruitingMenopause | Menopause Related ConditionsSingapore
-
University of ArkansasRecruitingMenopause Related ConditionsUnited States
-
Wake Forest University Health SciencesWithdrawnMenopause Related Conditions
-
I.M. Sechenov First Moscow State Medical UniversityCompletedMenopause Related ConditionsRussian Federation
Clinical Trials on Estrogens
-
Duramed ResearchCompleted
-
Duramed ResearchCompletedNocturnal Vasomotor SymptomsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest...TerminatedEndometrial CancerUnited States
-
Duramed ResearchCompleted
-
Northwestern UniversityNational Cancer Institute (NCI)Terminated
-
Duramed ResearchCompleted
-
University of Alabama at BirminghamCompletedVaginal Atrophy | Female Urogenital Diseases | Postmenopausal Symptoms | Postmenopausal Atrophic Vaginitis | Genitourinary DiseaseUnited States
-
Institute of Cancer Research, United KingdomUnknownBreast Cancer | Hot Flashes | Osteoporosis | Menopausal SymptomsUnited Kingdom
-
University of Texas Southwestern Medical CenterPfizer; University of Alabama at Birmingham; Women and Infants Hospital of Rhode...CompletedPelvic Organ Prolapse | Pelvic Floor Disorders | Cystocele | Uterine Prolapse | Vaginal Vault Prolapse | Vaginal Prolapse | Urogenital ProlapseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Uterine Diseases | Endometrial Hyperplasia | Menopause | Menopausal Complaints